Trial Profile
Open-Label Extended Administration of SCH 54031 (PEG Interferon Alfa-2b/PEG Intron) in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Paracetamol
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 14 Feb 2019 Status changed to completed.
- 19 Jun 2018 New trial record